

The world is racing to find safe and effective vaccines against COVID-19. And when we do, these vaccines must be made available to everyone who needs them regardless of nationality or wealth. Not only is this morally right but it is also the fastest way to end the pandemic. So as world leaders line up to make deals for COVID-19 vaccines candidates we want to know: **did this deal move us closer to, or further from, an equitable outcome?**

The Vaccine Access Test provides a framework to answer this question by evaluating deals between companies and countries using three metrics:

- **Prioritized:** Is this deal aligned with global guidelines on prioritizing allocation among at-risk populations?
- **Phased:** Does this deal allow for phased delivery of doses to ensure initial-supply is not monopolized?
- **Published:** Is the contracting processes transparent from start to finish?

Each metric is worth up to 2 points with the potential for 6 points total. **Here is how this deal stacks up.**

## DEAL SUMMARY

**Parties:** Pfizer and Mexico

**Date:** December 2, 2020

**Terms of Agreement:** Mexico has signed an agreement with Pfizer to acquire 34.4 million doses of its COVID-19 vaccine. Mexico received the first doses in December and expects about 1.4 million doses in January and a total of about 11.75 million by mid-year.

METRIC	SCORE	RATIONALE	<h2>Total Score: 3 out of 6</h2> <p>This deal provides some flexibility to ensure the initial supply of vaccines isn't monopolized by Mexico as it covers under 14% of the population and phases delivery.</p> <p>Subsequent deals could be improved by purchasing more closely against global population allocation guidelines. Pfizer could also disclose a break-down of how they arrived at their unit price, and what it costs to produce the vaccine.</p>
<b>Prioritized</b> 	1	34.4m doses would cover under 14% of Mexico's population with a 2-dose regimen, exceeding the 3% initial allocation threshold but within the threshold to prioritize the most vulnerable 20% population.	
<b>Phased</b> 	2	The deal includes phased delivery of doses. Ideally, the deal will allow for other countries to benefit from the initial supply and tier delivery of subsequent supply as it becomes available.	
<b>Published</b> 	0	Mexico has not listed details about the terms of deal and pricing online. Pfizer has not disclosed their pricing model.	

▲ Impeding Equity

Advancing Equity ▲